443 completed, 150 unknown, 77 terminated, 55 withdrawn. 780 Phase 1, 281 Phase 2.
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial | Phase 1 | Not yet recruiting | GlaxoSmithKline | 60 | 2027-01-25 | 2026-07-16 |
| Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19 | Phase 1 / Phase 2 | Not yet recruiting | Kimera Labs Inc. | 64 | 2027-01-01 | 2026-06-24 |
| Taurine Supplementation in Adolescents With Post-COVID Condition Taurine - Long COVID, Post COVID-19 Condition | Phase 1 / Phase 2 | Not yet recruiting | University of Alberta | 30 | 2026-12-30 | 2026-10-16 |
| Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS AVM0703, Placebo - ARDS, Covid19 | Phase 1 | Not yet recruiting | AVM Biotechnology Inc | 16 | 2026-12-01 | 2025-10-02 |
| Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) Keytruda - Post-Acute COVID-19 Syndrome | Phase 1 | Not yet recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 15 | 2026-11-02 | 2026-10-28 |
| Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years BMI2012 low-dose, Placebo low-dose, BMI2012 mid-dose - Prevention of COVID-19 Variant (Omicron JN.1) | Phase 1 | Not yet recruiting | BMI Korea | 72 | 2026-10-01 | 2026-08-28 |
| A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine RVX-sCPD9 - COVID -19 | Phase 1 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 80 | 2026-09-26 | 2026-10-16 |
| MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia MP101, Antibiotics - Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection | Phase 1 | Recruiting | MicrobiotiX Co., Ltd | 18 | 2026-07-25 | 2026-07-28 |
| Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants SARS-CoV-2 Omicron EG.5.1 challenge agent 10^5 TCID50, SARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50, SARS-CoV-2 Omicron EG.5.1 challenge agent 10^4 TCID50 - SARS-CoV-2 (COVID-19) | Phase 1 | Recruiting | Imperial College London | 38 | 2026-07-10 | 2026-07-17 |
| Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg - Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus) | Phase 1 | Not yet recruiting | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 90 | 2026-07-01 | 2026-06-10 |
| Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS Human umbilical cord mesenchymal stem cells + best supportive care, Placebo control + best supportive care - COVID-19, ARDS | Phase 1 / Phase 2 | Withdrawn | Baylx Inc. | 2026-06-01 | 2025-12-29 | |
| A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults OCU500 - COVID-19 | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 80 | 2026-05-26 | 2026-10-23 |
| A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial | Phase 1 | Active not recruiting | GlaxoSmithKline | 46 | 2026-05-15 | 2026-09-28 |
| A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet - Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19) | Phase 1 | Completed | Pfizer | 17 | 2026-04-13 | 2026-07-28 |
| A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19. MDX2301, Normal Saline - COVID -19, COVID-19 (Prevention) | Phase 1 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 80 | 2026-03-24 | 2026-09-10 |
| Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease Kisspeptin 112-121 - Reproductive Disorder, Neurodegeneration | Phase 1 | Recruiting | Stephanie B. Seminara, MD | 40 | 2026-03-10 | 2026-07-13 |
| Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial | Phase 1 | Active not recruiting | GlaxoSmithKline | 122 | 2026-03-10 | 2026-10-27 |
| A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine - Influenza, Human+COVID-19 | Phase 1 | Recruiting | GlaxoSmithKline | 225 | 2026-03-09 | 2026-06-30 |
| Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19 COVID-19 Vaccines - COVID - 19, SARS CoV-2 | Phase 1 | Active not recruiting | Rokote Laboratories Finland Oy | 20 | 2026-02-10 | 2026-07-22 |
| Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults PepGNP-COVID19, Sterile Water for Injection - COVID-19 | Phase 1 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2026-02-02 | 2026-05-15 |
Showing 20 of 780. Sign in to see all of them.
COVID-19 (675) · Coronavirus Infections (91) · Respiratory Distress Syndrome (35) · Severe Acute Respiratory Syndrome (28) · Virus Diseases (22) · Post-Acute COVID-19 Syndrome (14) · Pneumonia, Viral (13) · Infections (12) · Pneumonia, Bacterial (12) · Acute Lung Injury (11) · Pneumonia, Ventilator-Associated (11) · Pneumococcal Infections (10) · Pneumonia, Pneumococcal (10) · Influenza, Human (9)
Respiratory Tract Diseases (775) · Respiratory Tract Infections (771) · Infections (768) · Lung Diseases (766) · RNA Virus Infections (689) · Coronaviridae Infections (685) · Nidovirales Infections (685) · Pneumonia, Viral (673) · Virus Diseases (673) · Coronavirus Infections (595) · Pathological Conditions, Signs and Symptoms (90) · Pathologic Processes (78) · Respiration Disorders (51) · Disease Attributes (46)
Sodium Chloride (27) · Saline Solution (25) · Standard of Care (18) · nirmatrelvir and ritonavir drug combination (12) · Injections (11) · Ritonavir (11) · COVID-19 Vaccines (10) · BNT162 Vaccine (9) · nirmatrelvir (9) · Ivermectin (8) · 2019-nCoV Vaccine mRNA-1273 (7) · CVnCoV COVID-19 vaccine (6) · ChAdOx1 nCoV-19 (6) · casirivimab (6) · Acetylcysteine (5)
Pfizer (27) · National Institute of Allergy and Infectious Diseases (NIAID) (20) · GlaxoSmithKline (11) · AstraZeneca (10) · ImmunityBio, Inc. (8) · BioNTech SE (7) · Regeneron Pharmaceuticals (7) · Merck Sharp & Dohme LLC (6) · CanSino Biologics Inc. (5) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (5) · Sinocelltech Ltd. (5) · Sorrento Therapeutics, Inc. (5) · Stanford University (5) · D'Or Institute for Research and Education (4) · Massachusetts General Hospital (4)
United States (254) · China (87) · Australia (37) · United Kingdom (28) · Brazil (26) · Belgium (23) · South Korea (19) · Canada (18) · Russia (18) · France (17) · Germany (16) · Mexico (16) · South Africa (16) · Spain (15) · Israel (13)
Mike Royal, MD (4) · Fengcai Zhu, Doctor (3) · William Cameron, MD (3) · Yao Zhang (3) · Anya Loncaric (2) · Chang-Yi Wang, Ph.D. (2)
PMID 34473343, PMID 35713300, PMID 36435633, PMID 37231296, PMID 31986264, PMID 36147329, PMID 32125452, PMID 32257537, PMID 32896291, PMID 33873199, PMID 34551869, PMID 34658014, PMID 34890537, PMID 35316221, PMID 35547849, PMID 35660738, PMID 37354048, PMID 37699630, PMID 38181791, PMID 39636474, PMID 39749328, PMID 40632654, PMID 10051178, PMID 10415784, PMID 10669330, PMID 11023960, PMID 110688, PMID 11440640, PMID 11886437, PMID 12563677, PMID 1406879, PMID 14719037, PMID 15663512, PMID 15774846, PMID 15882530, PMID 16011702, PMID 16051812, PMID 16304338, PMID 16625202, PMID 16787239, PMID 17181919, PMID 17391816, PMID 17954801, PMID 18046534, PMID 18073382, PMID 18097874, PMID 18369153, PMID 18552864, PMID 18778201, PMID 19355966
2023 (7), 2018 (2), 5UM1AI148373-05 (2), 5UM1AI148684-02 (2), 2009 (1), 2015 (1), 2025 (1), 272201300017C-18-0-1 (1), P30CA033572 (1), P30CA047904 (1), P30CA138292 (1), R01HL109448 (1), R21DC014567 (1), R37HD043341 (1), R44HL066965 (1)